A druglikeness-first approach that searches large chemical spaces to deliver lead-ready compounds
The Drug Discovery Bottleneck
After nearly 25 years in drug discovery, I’ve watched the same pattern repeat. Programs identify modest hits, then spend five to seven years attempting to optimize toward a clinical candidate – most of which never materialize. The failures are rarely due to target affinity. Instead, they stem from ADME, PK, toxicity, and developability issues that surface late, when the cost of failure is highest.
Yet modern drug discovery – both experimental and computational – remains overwhelmingly affinity-first.
Computationally, this constraint no longer applies.
So, we inverted the problem.
Druglikeness First, Not as a Filter
Denovicon’s multi-objective optimization (MOO) platform searches a large, chemically diverse space covering trillions of molecules for leads that are drug-like from the outset, optimized simultaneously across multiple developability-relevant properties before target matching.
This is not a sequential workflow and not a post-hoc filtering step.
Instead, drug-relevant constraints are embedded directly into the optimization process, enabling the platform to identify molecules that satisfy competing requirements in a single, unified search.
The result is lead-quality molecules, not modest hits – and chemistry that medicinal teams can interrogate and advance with confidence.
Interpretable Chemistry at Scale
Unlike many generative approaches that rely on opaque latent representations, Denovicon’s platform is designed to produce outputs that support chemical interpretability and rational follow-up, enabling clear structure–property and structure–activity reasoning during optimization.
This allows discovery teams to understand why a molecule works, not just that it works – reducing downstream risk and accelerating decision-making.
Validated in a Real Drug Discovery Program
Denovicon’s approach has already been validated in practice. Using its physics-driven AI platform, Denovicon delivered a 4nM PARP7 inhibitor with 2000/2500× selectivity over PARP1/PARP2 in less than a year (including experimental data; virtual design took less than 2 days!). This makes it as potent at PARP7, while achieving a substantial selectivity advantage over the clinical compound RBN-2397 (PARP7 = 3nM; PARP1 = 37nM; PARP2 = 17nM).
The new multi-objective optimization platform builds on this proven foundation, extending its ability to search larger chemical spaces while optimizing across all key drug-relevant properties simultaneously.
Built for Scale, Ready for the Future
The platform is production-ready today, while architected for future compatibility with emerging computational hardware – allowing Denovicon to take advantage of new acceleration technologies as they mature, without changing the underlying discovery workflow.
About Denovicon Therapeutics
Denovicon Therapeutics is a biotechnology company developing physics-driven AI- and physics-based computational platforms that run on current and next-generation hardware to transform small-molecule drug discovery by delivering lead-ready compounds through scalable, interpretable multi-objective optimization.